Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer. - Colca JR; VanderLugt JT; Adams WJ; Shashlo A; McDonald WG; Liang J; Zhou R; Orloff DG (Clinical pharmacology and therapeutics, 2013)